Introduction: Multiple myeloma (MM) is a clinically heterogeneous malignancy in which outcomes remain difficult to predict using static baseline risk models. Increasing attention has shifted toward dynamic prognostic markers, including early disease progression and early mortality; however, their relative prognostic value—particularly the optimal definition of early progression—and their integration with patient-related factors remain insufficiently defined in real-world populations. Methods: We retrospectively analysed 207 newly diagnosed MM patients treated between 2018 and 2023. Early disease progression was defined as progression within 18 (POD18) and 24 months (POD24) from treatment initiation. Early mortality was defined as death within six months of diagnosis. Overall survival (OS) and progression-free survival (PFS) were analysed using Kaplan–Meier estimates and Cox regression models, including time-dependent analyses. Results: During a median follow-up of 60 months, POD18 occurred in 44.0% and POD24 in 51.2% of patients. POD18 was strongly associated with inferior OS (HR 9.38; 95% CI 5.98–14.70; p < 0.0001) and demonstrated superior prognostic discrimination compared with POD24 (C-index 0.742 vs. 0.719). In multivariable analysis, POD18 remained the strongest independent predictor of OS, alongside comorbidity burden and performance status. Early mortality occurred in 17.9% of patients and was independently associated with advanced disease stage. Time-dependent modelling showed that the prognostic impact of baseline staging decreased over time, supporting the dynamic nature of risk in MM. Conclusion: POD18 is a robust and clinically informative dynamic prognostic marker that outperforms POD24 in predicting survival in real-world patients with MM. Integration of early disease kinetics with baseline disease burden and comorbidity burden provides a pragmatic framework for dynamic risk stratification, particularly in settings with limited access to comprehensive molecular profiling.
1 January 2024 in Srpski medicinski casopis Lekarske komore
Introduction: According to the results of previous research, it was found that the dysfunction of the insulin-like growth factor (IGF) system, which is the basis of insulin resistance with hyperinsulinemia, acts as a proliferative tumor factor, and its neoplastic potential is also exhibited in multiple myeloma. Study aim: The study aims to determine whether there is an association between insulin resistance in patients newly diagnosed with multiple myeloma (NDMM) and the achieved therapeutic response after induction chemotherapy. Materials and methods: The prospective study included 35 NDMM patients (60% women and 40% men), treated at the Clinical Center of Vojvodina Clinic for Hematology. Glycemia and insulinemia levels were determined after fasting and postprandially, upon which the values of HOMA-IRIf (after fasting) and HOMA-IRIpp (postprandially) were calculated. HOMA-IRI values > 2.2 were the criteria for insulin resistance. The analyses were performed twice - before the initial chemotherapy and after the completion of the treatment. The therapeutic response was evaluated according to the criteria of the Serbian Myeloma Group (SMG) and the International Myeloma Working Group IMWG). Statistical analyses were performed in the SPSS program, Version 22. Results: The average patient age was 63.85 years. In total, 86% of patients responded favorably to the therapy. The average value of HOMA-IRIf before treatment was 1.82 ± 0.79 and it was 1.80 ± 0.72 after therapy. The central median value of HOMA-IRIpp before treatment was 5.46, with an interquartile range of 1.07 - 20.57, and after treatment, it was 5.86 with an interquartile range of 1.22 - 28.22. A significant negative correlation between HOMA-IRIf after applied treatment and achieved therapeutic response was observed, (p = 0.040). Conclusion: Active concomitant therapy of insulin resistance in NDMM could improve the response to applied antimyeloma treatment.